OncoZenge
5.28 SEK
+4.76 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+4.76 %
-21.89 %
-19.39 %
-6.88 %
-17.63 %
-24.57 %
-13.44 %
-
-56.85 %
OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Read moreMarket cap
66.78M SEK
Turnover
106.22K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18/2
2026
Annual report '25
20/5
2026
Interim report Q1'26
27/5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds
OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools